ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • D Vucic - , Genentech Incorporated (Autor:in)
  • H R Stennicke - , The Burnham Institute, La Jolla, California (Autor:in)
  • M T Pisabarro - , Strukturelle Bioinformatik (FoG), Biotechnologisches Zentrum (BIOTEC), Genentech Incorporated (Autor:in)
  • G S Salvesen - , The Burnham Institute, La Jolla, California (Autor:in)
  • V M Dixit - , Genentech Incorporated (Autor:in)

Abstract

BACKGROUND: Inhibitors of apoptosis (IAPs) are a family of cell death inhibitors found in viruses and metazoans. All IAPs have at least one baculovirus IAP repeat (BIR) motif that is essential for their anti-apoptotic activity. IAPs physically interact with a variety of pro-apoptotic proteins and inhibit apoptosis induced by diverse stimuli. This allows them to function as sensors and inhibitors of death signals that emanate from a variety of pathways.

RESULTS: Here we report the characterization of ML-IAP, a novel human IAP that contains a single BIR and RING finger motif. ML-IAP is a powerful inhibitor of apoptosis induced by death receptors and chemotherapeutic agents, probably functioning as a direct inhibitor of downstream effector caspases. Modeling studies of the structure of the BIR domain revealed it to closely resemble the fold determined for the BIR2 domain of X-IAP. Deletion and mutational analysis demonstrated that integrity of the BIR domain was required for anti-apoptotic function. Tissue survey analysis showed expression in a number of embryonic tissues and tumor cell lines. In particular, the majority of melanoma cell lines expressed high levels of ML-IAP in contrast to primary melanocytes, which expressed undetectable levels. These melanoma cells were significantly more resistant to drug-induced apoptosis.

CONCLUSIONS: ML-IAP, a novel human IAP, inhibits apoptosis induced by death receptors and chemotherapeutic agents. The BIR of ML-IAP possesses an evolutionarily conserved fold that is necessary for anti-apoptotic activity. Elevated expression of ML-IAP renders melanoma cells resistant to apoptotic stimuli and thereby potentially contributes to the pathogenesis of this malignancy.

Details

OriginalspracheEnglisch
Seiten (von - bis)1359-1366
Seitenumfang8
FachzeitschriftCurrent Biology
Jahrgang10
Ausgabenummer21
PublikationsstatusVeröffentlicht - 13 Nov. 2000
Peer-Review-StatusJa

Externe IDs

Scopus 0034597630

Schlagworte

Schlagwörter

  • Adaptor Proteins, Signal Transducing, Adult, Amino Acid Motifs, Amino Acid Sequence, Antigens, CD/metabolism, Antineoplastic Agents/pharmacology, Apoptosis/drug effects, Carrier Proteins/chemistry, Caspase Inhibitors, Caspases/genetics, Cell Line, Doxorubicin/pharmacology, Genes, Reporter, Humans, Inhibitor of Apoptosis Proteins, Melanocytes/metabolism, Melanoma/genetics, Microscopy, Fluorescence, Models, Molecular, Molecular Sequence Data, Mutagenesis, Site-Directed, Neoplasm Proteins/chemistry, Protein Conformation, Protein Structure, Tertiary, Receptors, TNF-Related Apoptosis-Inducing Ligand, Receptors, Tumor Necrosis Factor/metabolism, Receptors, Tumor Necrosis Factor, Type I, Recombinant Fusion Proteins/metabolism, Sequence Alignment, Tumor Cells, Cultured, fas Receptor/metabolism